Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + cytarabine + carmustine + etoposide + melphalan
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
This multi-agent chemotherapy regimen was developed by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of newly diagnosed primary central nervous system lymphoma (PCNSL). The protocol consists of an intensive induction phase using high-dose methotrexate and cytarabine (Ara-C), which are selected for their ability to penetrate the blood-brain barrier. This is followed by a consolidation phase involving high-dose BEAM chemotherapy—comprising carmustine, etoposide, cytarabine, and melphalan—and autologous peripheral blood stem cell transplantation (ASCT). The regimen aims to achieve deep remission through antimetabolite-mediated inhibition of DNA synthesis during induction, followed by myeloablative conditioning to eliminate residual disease in the CNS and systemic compartments.
- Other names
- methotrexate-Memorial Sloan Kettering Cancer Center-primary central nervous system lymphomaMSKCC PCNSL ProtocolIntensive Methotrexate and Cytarabine followed by BEAM and ASCTMTX-Ara-C-BEAM
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)DNA polymerase familyDNA
Beyond the preview
Go deeper on methotrexate + cytarabine + carmustine + etoposide + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + cytarabine + carmustine + etoposide + melphalan.